ICAD - צמיחת מכירות משנה לשנה (TTM) iCAD, Inc.

iCAD, Inc. (ICAD) maintains an impeccable reputation in the field of AI-driven oncology diagnostics, ensuring the highest accuracy in mammography analysis. This is complemented by the implementation of MRI software, which creates a steady stream of recurring payments. The year-over-year commercial revenue dynamics for the trailing year confirm this growth, where -24.50 captures the magnitude of this parameter. Business stability is further supported by streamlined logistics and a diversified warehouse network for the prompt delivery of equipment.
פילוחי נתונים אנליטיים מרוכזים עבור icadmed.com (ICAD)

iCAD, Inc. (ICAD) development of non-invasive cancer diagnostic systems as part of its ESG strategy requires continuous expansion of its market presence. This chart of trailing 12-month year-over-year revenue growth measures the dynamics of total annual sales compared to the same period, allowing for an assessment of the business's actual scaling speed. The positive trend confirms the commercial demand for the technologies, helping investors balance potential returns against the risks of asset drawdowns.